ObjectiveThe prognostic effect of miR-196a/b expression in adult patients with leukaemia remains unclear. This study aimed to determine whether miR-196a/b expression can serve as a prognostic factor for patients with acute myeloid leukaemia.MethodsWe enrolled 124 patients with acute myeloid leukaemia. We measured miR-196a/b expression by real-time reverse transcription-polymerase chain reaction. We classified patients into high and low expression groups based on the median expression value. Cox regression analyses were carried out to assess the prognostic significance of miR-196a/b expression in the context of well-established predictors.ResultsPatients with high miR-196a/b expression were older in age, and had higher white blood cell and platelet counts than did patients with low miR-196a/b expression. Patients with high miR-196a/b expression were associated with the French–American–British classification M5 subtype and with the presence of nucleophosmin and FLT3 internal tandem duplication mutations, but were not associated with the favourable karyotype risk subgroup. Moreover, patients with high miR-196a/b expression had a shorter event-free survival rate compared with those with low miR-196a/b expression in univariate and multivariate analyses.ConclusionHigh miR-196a/b expression is associated with poor event-free survival.
Background: Multiple myeloma (MM) is a hematologic malignancy that originate from a malignant clone of plasma cells. This study aimed to discover the reduction rate of monoclonal (M) protein after first and fourth cycle chemotherapy, which acts as a new prognostic factor for progression-free survival (PFS) in MM patients. Methods: We retrospectively analyzed 164 patients with MM. The overall survival (OS) and PFS from the time of first diagnosis were measured. Cox proportional hazards model was used to evaluate if the reduction rate of M protein after first to fourth cycle chemotherapy effect PFS and OS. . Results: Multivariate analysis was performed with factors including del(17p), t(14;16), t(14;20), ISS stage, age, AST and others parameters. The reduction rate of M protein after first cycle chemotherapy (C1reduction rate) (P<0.001) and the reduction rate of M protein after fourth cycle chemotherapy (C4 reduction rate) (P<0.001) acts as dependent predictors of PFS. The 36 months PFS rate in patients with a reduction rate of M protein after the first cycle chemotherapy was compared. The reduction rate of ≥25 vs <25% showed no difference, while the reduction rate of ≥50 vs <50% showed significant difference in PFS. Meanwhile, the reduction rate of M protein after the fourth cycle chemotherapy ≥25 vs <25%, ≥50 vs <50% showed no meaning, but the groups of ≥75 vs <75% showed significant differences in PFS. The patients with higher reduction rate in these two stages had longer PFS. Conclusions :Higher reduction rate of M protein after first and and fourth cycle of chemotherapy act as advantageous prognostic factors for PFS in MM patients in the initial diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.